# Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection

> **NCT04509999** · PHASE3 · WITHDRAWN · sponsor: **University of Florida**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Bicalutamide 150 Mg Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04509999
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10-26
- **Primary completion:** 2021-06-30
- **Final completion:** 2021-06-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients enrolled and funding withdrawn
- **Last updated:** 2021-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04509999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04509999, "Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04509999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*